SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
OSI Pharmaceuticals (OSIP) - formerly Oncogene
An SI Board Since December 1997
Posts SubjectMarks Bans Symbol
447 40 0 OSIP
Emcee:  James Reynolds Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
422Pfizer terminates Macugen agreement: OSIP, up after hours on decent earnings, qutuck-4/26/2007
421Merrill on Erbitux flop in pancreatic cancer. Erbitux negative, competition redtom pope-4/11/2007
420Merrill again:(buy) Likely Impact of 2Q Erbitux Pancreatic Data Modest Based ontom pope-3/8/2007
419Merrill: OSI Pharmaceuticals, Inc. (OSIP, US$33.51, C-1-9) We reiterate our buytom pope-1/30/2007
418OSIP resumes its slide. I should know better than to rely on a Merrill recommendtom pope-1/18/2007
417Merrill: Tarceva sales better than reduced expectations DNA reported U.S. Tarcetom pope-1/11/2007
4168-K, dated yesterday On January 4, 2007, Prosidion Limited ("Prosidion&quotom pope-1/11/2007
415Merrill - it's kept its buy through quite a downslope: OSI Licensed key diatom pope-1/8/2007
414LLY, OSIP Ink Diabetes Deal >>Friday January 5, 8:00 am ET Lilly Granttuck-1/5/2007
413Embargo or no embargo.. Surgery is four weeks after Avastin....well this changeMiljenko Zuanic-11/9/2006
412Thanks, 18% RR and 50% control rate isn't bad for A-T arm. It appears that Miljenko Zuanic-11/2/2006
411fwiw: medpagetoday.com from masterlongevity off ihubformer_pgs-11/2/2006
410To be featured at EORTC-ACCR, Prague. "Remarkable results from treating kiMiljenko Zuanic-11/2/2006
409PFE Licenses RNAi Approach to Treating AMD from Quark Biotech: investorshub.comDewDiligence_on_SI-9/26/2006
408Interesting assay developed by Acadia(!) suggests that Tarceva might get a littltuck-9/15/2006
407OSI Requires Leap of Faith By Marc Lichtenfeld Senior Columnist 8/21/2006 10:49Doc Bones-8/21/2006
406After getting approved by the FDA for first line pancreatic cancer, Tarceva flamtuck-7/28/2006
405EyeTech ace in the hole? Don’t believe it: investorshub.comDewDiligence_on_SI-7/7/2006
404Re: Phase-4 Macugen “maintenance” trial biz.yahoo.com <i>In this open laDewDiligence_on_SI-6/26/2006
403ML, from yesterday: Encouraging early data for PSN9301 in type 2 diabetes OSI Ptom pope-6/15/2006
402LLY Presents 3-Yr Ruboxistaurin Data in Diabetic Retinopathy investorshub.comDewDiligence_on_SI-6/12/2006
401OSI and INGN 241: synergy in preclinical results: Message 22511542 For what lituck-6/4/2006
400ML's take: PIER Disappoints; Still Positive on Lucentis Genentech released tom pope-6/2/2006
399>>Preliminary Results from a Phase IIIb Study Showed Patients With Wet AMDtuck-6/2/2006
398I think some anticipation of ASCO buzz from Tarceva/Avastin combo in lung cancertuck-6/1/2006
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News